Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $17.00.

A number of brokerages have weighed in on TEVA. Jefferies Financial Group increased their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $20.00 price objective (up from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, June 5th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 20th. Finally, Bank of America increased their price objective on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, May 30th.

Insider Activity

In related news, CAO Amir Weiss sold 15,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total value of $260,400.00. Following the transaction, the chief accounting officer now directly owns 17,814 shares in the company, valued at $299,275.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Amir Weiss sold 15,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $16.80, for a total value of $260,400.00. Following the completion of the sale, the chief accounting officer now directly owns 17,814 shares of the company’s stock, valued at approximately $299,275.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 549,719 shares of company stock worth $9,353,736. 0.55% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TEVA. Edmond DE Rothschild Holding S.A. raised its position in Teva Pharmaceutical Industries by 4.0% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock worth $346,000 after purchasing an additional 947 shares during the period. Desjardins Global Asset Management Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 15.2% in the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock worth $85,000 after buying an additional 1,070 shares during the period. Oppenheimer & Co. Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 9.6% in the 1st quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after acquiring an additional 1,180 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 67,996 shares of the company’s stock valued at $688,000 after acquiring an additional 1,375 shares during the period. Finally, Transcend Capital Advisors LLC grew its position in Teva Pharmaceutical Industries by 13.6% during the 4th quarter. Transcend Capital Advisors LLC now owns 12,543 shares of the company’s stock worth $131,000 after acquiring an additional 1,500 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Up 1.5 %

Shares of TEVA stock opened at $16.80 on Thursday. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. The firm has a market cap of $19.03 billion, a P/E ratio of -40.98, a PEG ratio of 1.54 and a beta of 0.90. The company has a 50 day moving average of $16.21 and a 200-day moving average of $13.82. Teva Pharmaceutical Industries has a 12-month low of $7.42 and a 12-month high of $17.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). The firm had revenue of $3.82 billion for the quarter, compared to the consensus estimate of $3.70 billion. Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. Sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.32 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.